The Biden administration released prices or the first 10 medications subject to historic negotiations between the federal Medicare program and drugmakers.
But the announcement is just the beginning of a controversial, multi-round process that could produce more savings for taxpayers and older Americans and put more pressure on pharmaceutical companies over time.
It’s a key provision of President Joe Biden’s signature Inflation Reduction Act, which was signed into law two years ago.